Neurocrine Biosciences Inc
NASDAQ: NBIX
$138.97
-$1.12 (-0.8%)
Closing price April 24, 2024
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Aqua America, CenterPoint Energy, Ferrari, GameStop, Medtronic, Roku, Salesforce.com and Uber Technologies.
Published:
The top analyst upgrades, downgrades and initiations seen on Monday included Amazon.com, Dover, Facebook, Lam Research, Newmont Mining, Occidental Petroleum, Six Flags, Tesla and 3D Systems.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday included Arena Pharmaceuticals, Autodesk, Coca-Cola, General Electric, Marvell, Monster Beverages, Nabors and Procter &...
Published:
Last Updated:
Wells Fargo, Weatherford International, Huntington Bancshares, and Neurocrine Biosciences all posted new 52-week lows Wednesday.
Published:
Last Updated:
Neurocrine Bio shares dipped on Wednesday after the company announced that its midstage Tourette syndrome study did not live up to expectations.
Published:
Last Updated:
A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove to be huge.
Published:
Last Updated:
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday include Amazon, Anthem, Constellation Brands, Hecla Mining, Nike, Overstock.com and UnitedHealth.
Published:
Last Updated:
Four top growth stocks could be great trades for the balance of 2018 and good to hold into the coming years as they all stand to have continued revenue growth and are solid players in their...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Published:
Last Updated:
While these four stocks are better suited for accounts that have a higher risk tolerance, they all make good sense now and all have outstanding upside potential.
Published:
Last Updated:
While there is no guarantee that these four biotech companies are acquired, they are outstanding stocks to own in aggressive growth portfolios on their own.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS and Vertex Pharmaceuticals.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Avis Budget, Blue Apron, Chipotle Mexican Grill, Domino's, Northrop Grumman, Pepsico, Rio Tinto, T-Mobile and...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Accenture, Ericsson, General Motors, Phillips 66, United Rentals, Urban Outfitters, Xerox and Yum Brands.
Published:
Last Updated: